Loading...
XTAI
4155
Market cap79mUSD
Jul 15, Last price  
15.90TWD
1D
-0.31%
1Q
-8.36%
Jan 2017
-35.86%
IPO
-42.50%
Name

OK Biotech Co Ltd

Chart & Performance

D1W1MN
P/E
24.88
P/S
1.40
EPS
0.64
Div Yield, %
3.77%
Shrs. gr., 5y
9.81%
Rev. gr., 5y
6.11%
Revenues
1.67b
+40.11%
280,794,000405,990,000502,536,000656,695,0001,074,281,000633,765,000856,551,0001,040,462,0001,233,076,0001,120,346,0001,241,252,0001,484,413,0001,263,378,0001,483,523,0001,191,985,0001,670,033,000
Net income
94m
+3,087.75%
49,700,00037,736,00072,340,00096,678,000138,205,00071,364,000110,969,00085,201,000126,809,000161,362,000125,760,000129,728,00031,422,000143,462,0002,948,00093,975,000
CFO
66m
+2,146.95%
6,950,000-19,515,00093,117,00079,173,00087,085,000-33,834,000289,435,000260,724,000102,768,000128,750,00045,177,000147,700,00021,896,000240,526,0002,933,00065,903,000
Dividend
Sep 05, 20240.6 TWD/sh
Earnings
Aug 07, 2025

Profile

OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
URL
https://www.okbiotech.com/
IPO date
Dec 30, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,670,033
40.11%
1,191,985
-19.65%
1,483,523
17.43%
Cost of revenue
1,629,558
1,190,220
1,343,386
Unusual Expense (Income)
NOPBT
40,475
1,765
140,137
NOPBT Margin
2.42%
0.15%
9.45%
Operating Taxes
20,791
9,620
38,868
Tax Rate
51.37%
545.04%
27.74%
NOPAT
19,684
(7,855)
101,269
Net income
93,975
3,087.75%
2,948
-97.95%
143,462
356.57%
Dividends
(44,118)
(144,640)
(94,934)
Dividend yield
1.51%
4.49%
2.94%
Proceeds from repurchase of equity
270,000
BB yield
-8.38%
Debt
Debt current
423,663
238,868
394,501
Long-term debt
393,356
99,469
392,434
Deferred revenue
Other long-term liabilities
24
24
24
Net debt
517,322
(373,619)
(298,005)
Cash flow
Cash from operating activities
65,903
2,933
240,526
CAPEX
(374,273)
(429,677)
(294,241)
Cash from investing activities
(444,928)
(358,382)
(294,230)
Cash from financing activities
338,025
82,063
50,269
FCF
(1,001,987)
(155,399)
(92,469)
Balance
Cash
290,500
365,340
636,644
Long term investments
9,197
346,616
448,296
Excess cash
216,195
652,357
1,010,764
Stockholders' equity
1,634,907
1,538,388
1,264,038
Invested Capital
3,130,176
2,075,736
1,582,552
ROIC
0.76%
6.80%
ROCE
1.20%
0.06%
5.40%
EV
Common stock shares outstanding
142,582
128,403
132,380
Price
20.45
-18.53%
25.10
2.74%
24.43
17.96%
Market cap
2,915,809
-9.53%
3,222,915
-0.34%
3,234,044
29.70%
EV
3,507,975
2,846,541
2,937,826
EBITDA
112,897
77,312
208,019
EV/EBITDA
31.07
36.82
14.12
Interest
6,230
8,997
11,424
Interest/NOPBT
15.39%
509.75%
8.15%